Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review
MD Islam, WA Kaplan, D Trachtenberg… - Globalization and …, 2019 - Springer
Background We present a systematic review describing ex-ante and ex-post evaluations of
the impacts of intellectual property provisions in trade treaties on access to medicine in low …
the impacts of intellectual property provisions in trade treaties on access to medicine in low …
[HTML][HTML] Intellectual property rights and pharmaceuticals: challenges and opportunities for economic research
IM Cockburn - The economics of intellectual property, 2009 - books.google.com
The pharmaceutical sector has unusual prominence in debates about IP policy, and has
served as the front line for national and international controversies about the relationship …
served as the front line for national and international controversies about the relationship …
Firm level profitability determinants in Indian drugs and pharmaceutical industry
S Tyagi, DK Nauriyal - International Journal of Pharmaceutical and …, 2017 - emerald.com
Purpose This paper aims to analyze the firm level determinants of profitability of Indian drug
and pharmaceutical industry which is known for historically weak R&D initiatives …
and pharmaceutical industry which is known for historically weak R&D initiatives …
[图书][B] Pharmaceutical industry and public policy in post-reform India
RK Joseph - 2015 - taylorfrancis.com
This book examines the impact of economic reforms in India on the pharmaceutical industry
and access to medicines. It traces the changing production and trade pattern of the industry …
and access to medicines. It traces the changing production and trade pattern of the industry …
Generic entry into the regulated Spanish pharmaceutical market
I Moreno-Torres, J Puig-Junoy, JR Borrell - Review of Industrial …, 2009 - Springer
This paper empirically analyses entry by generic firms into the strictly regulated Spanish
pharmaceutical market. We estimate a fixed effects negative binomial entry model using a …
pharmaceutical market. We estimate a fixed effects negative binomial entry model using a …
The price of medicines in Jordan: the cost of trade-based intellectual property
RB Abbott, R Bader, L Bajjali… - Journal of Generic …, 2012 - journals.sagepub.com
Jordan dramatically strengthened the level of intellectual property protection it provides for
pharmaceutical products in consequence of joining the World Trade Organization in 2000 …
pharmaceutical products in consequence of joining the World Trade Organization in 2000 …
Perspectives on COVID-19 vaccine
I Borowy - Historical Social Research/Historische Sozialforschung …, 2021 - JSTOR
COVID-19 has been the deadliest pandemic since the Spanish flu of 1918–1920. While
people in the twentieth century had to wait for the pandemic to run its course before life …
people in the twentieth century had to wait for the pandemic to run its course before life …
Does one size fit all? Patents, the right to health and access to medicines
JA Sellin - Netherlands International Law Review, 2015 - Springer
The question posed in this article is whether the right to health and patents conflict or
coexist. This question is examined from the perspective of the issue of access to affordable …
coexist. This question is examined from the perspective of the issue of access to affordable …
The effects of intellectual property rights on access to medicines and catastrophic expenditure
Y Jung, S Kwon - International Journal of Health Services, 2015 - journals.sagepub.com
Since the introduction of Trade-Related Aspects of Intellectual Property Rights (TRIPS) in
1995, there has been considerable concern that poor access to essential medicines in …
1995, there has been considerable concern that poor access to essential medicines in …
[PDF][PDF] Access to medicines: The interface between patents and human rights. Does one size fit all?
JA Sellin - 2014 - cris.maastrichtuniversity.nl
The subject of this dissertation is the issue of access, or lack thereof, of medicines for
patients in developing countries. The argument often made in that regard is that patent …
patients in developing countries. The argument often made in that regard is that patent …